Epstein-Barr B-virus B-virus
virus E-virus E-virus
human B-virus B-virus
papillomaviruses E-virus E-virus
human B-virus B-virus
tumor I-virus I-virus
viruses E-virus E-virus
infect O O
replicate O O
upper O O
aerodigestive O O
tract O O
epithelia O O
cause O O
head O O
neck O O
cancers O O
. O O

The O O
productive O O
phases O O
viruses B-virus B-virus
tied O O
stratified O O
epithelia O O
highlighting O O
possibility O O
viruses B-virus B-virus
may O O
affect O O
's O O
life O O
cycles O O
. O O

Our O O
lab O O
established O O
vitro O O
model O O
system O O
test O O
effects O O
EBV B-virus B-virus
HPV B-virus B-virus
co-infection O O
stratified O O
squamous O O
oral O O
epithelial O O
cells O O
. O O

Our O O
results O O
indicate O O
HPV B-virus B-virus
increases O O
maintenance O O
EBV B-virus B-virus
genome O O
co-infected O O
cells O O
promotes O O
lytic O O
reactivation O O
EBV B-virus B-virus
upper O O
layers O O
stratified O O
epithelium O O
. O O

Expression O O
HPV B-virus B-virus
oncogenes O O
E6 O O
E7 O O
found O O
necessary O O
sufficient O O
account O O
HPV-mediated B-virus O
lytic O O
reactivation O O
EBV B-virus B-virus
. O O

Our O O
findings O O
indicate O O
HPV B-virus B-virus
increases O O
capacity O O
epithelial O O
cells O O
support O O
EBV B-virus B-virus
life O O
cycle O O
, O O
could O O
turn O O
increase O O
EBV-mediated B-virus O
pathogenesis O O
oral O O
cavity O O
. O O

The O O
influenza B-virus B-virus
A I-virus I-virus
virus E-virus E-virus
components O O
live O O
, O O
attenuated O O
influenza O O
vaccine O O
( O O
LAIV O O
) O O
encode O O
HA O O
NA. O O
gene O O
segments O O
circulating O O
virus B-virus B-virus
strain O O
remaining O O
gene O O
segments O O
cold-adapted O O
master O O
donor B-virus O
virus E-virus B-virus
, O O
A/Ann B-virus O
Arbor/6/1960 E-virus O
( O O
H2N2 B-virus B-virus
) O O
. O O

The O O
master O O
donor B-virus B-virus
virus E-virus E-virus
imparts O O
least O O
three O O
phenotypes O O
: O O
temperature-sensitivity O O
( O O
ts O O
) O O
, O O
attenuation O O
( O O
att O O
) O O
, O O
cold-adaption O O
( O O
ca O O
) O O
. O O

The O O
genetic O O
loci O O
responsible O O
att O O
ts O O
phenotypes O O
LAIV O O
mapped O O
PB1 O O
, O O
PB2 O O
, O O
NP O O
reverse O O
genetics O O
experiments O O
using O O
immortalized O O
cell O O
lines O O
. O O

However O O
, O O
vivo O O
studies O O
demonstrated O O
M O O
segment O O
, O O
acquired O O
alanine O O
( O O
Ala O O
) O O
serine O O
( O O
Ser O O
) O O
mutation O O
M2 O O
position O O
86 O O
cold O O
adaption O O
- O O
mutation O O
found O O
influenza B-virus B-virus
A I-virus I-virus
virus E-virus E-virus
strain O O
- O O
contributes O O
att O O
phenotype O O
. O O

Prior O O
studies O O
shown O O
region O O
M2 O O
cytoplasmic O O
tail O O
critical O O
influenza B-virus B-virus
virus E-virus E-virus
replication O O
. O O

Using O O
reverse O O
genetics O O
, O O
demonstrate O O
certain O O
amino O O
acid O O
substitutions O O
M2 O O
positions O O
83 O O
86 O O
alter O O
replication O O
influenza B-virus B-virus
A/Udorn/307/72 E-virus O
( O O
H3N2 B-virus B-virus
) O O
. O O

Importantly O O
, O O
substitution O O
Ser O O
M2 O O
position O O
86 O O
reduces O O
A/Udorn/307/72 B-virus O
replication O O
differentiated O O
primary O O
human O O
nasal O O
epithelial O O
cell O O
( O O
hNECs O O
) O O
cultures O O
, O O
considerably O O
affect O O
replication O O
MDCK O O
cells O O
. O O

When O O
Ser O O
substituted O O
Ala O O
M2 O O
86 O O
LAIV O O
, O O
virus B-virus B-virus
replicated O O
higher O O
titers O O
faster O O
kinetics O O
hNEC O O
cultures O O
, O O
implicating O O
amino O O
acid O O
change O O
contributing O O
LAIV O O
attenuation O O
. O O

Increased O O
replication O O
also O O
resulted O O
increased O O
production O O
IFN-位 O O
. O O

These O O
data O O
indicate O O
LAIV O O
associated O O
Ser O O
mutation O O
M2 O O
position O O
86 O O
contributes O O
att O O
phenotype O O
associated O O
differential O O
regulation O O
interferon O O
LAIV O B-virus
infection O O
. O O

We O O
developed O O
custom-made O O
reference O O
genome O O
comprises O O
human O O
chromosomes O O
along O O
annotated O O
genome O O
143 O O
HPV B-virus B-virus
types O O
pseudochromosomes O O
. O O

The O O
tool O O
runs O O
dual O O
mode O O
defined O O
user O O
: O O
'quick O O
mode O O
' O O
identify O O
presence O O
HPV B-virus B-virus
types O O
'integration O O
mode O O
' O O
determine O O
genomic O O
location O O
site O O
integration O O
. O O

The O O
input O O
data O O
paired-end O O
whole-exome O O
, O O
whole-genome O O
whole-transcriptome O O
data O O
set O O
. O O

The O O
HPVDetector B-virus O
available O O
public O O
domain O O
download O O
: O O
http O O
: O O
//www.actrec.gov.in/pi-webpages/AmitDutt/HPVdetector/HPVDetector.html O O
. O O

Each O O
adenovirus O O
included O O
small O O
deletion O O
( O O
) O O
E1a O O
region O O
genome O O
( O O
24 O O
CB016 O O
) O O
intended O O
allow O O
selective O O
replication O O
HPV-positive B-virus B-virus
cells O O
. O O

In O O
vitro O O
assays O O
performed O O
analyze O O
transduction O O
efficiency O O
vectors O O
cell O O
viability O O
following O O
viral O O
infection O O
. O O

Then O O
, O O
UPCI O O
SCC090 O O
cell O O
line O O
( O O
HPV-positive B-virus B-virus
) O O
used O O
establish O O
subcutaneous O O
tumors O O
flanks O O
nude O O
mice O O
. O O

The O O
tumors O O
treated O O
either O O
one O O
dose O O
virus B-virus B-virus
four O O
doses O O
( O O
injected O O
every O O
fourth O O
day O O
) O O
. O O

The O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
comprises O O
heterogeneous O O
group O O
double-strand O O
DNA O O
viruses B-virus B-virus
variable O O
potential O O
infect O O
human O O
epithelial O O
cells O O
trigger O O
neoplastic O O
transformation O O
. O O

Its O O
8 O O
kb O O
genome O O
encodes O O
proteins O O
required O O
virus B-virus B-virus
replication O O
self-organized O O
formation O O
infectious O O
particles O O
also O O
early O O
proteins O O
E6 O O
E7 O O
able O O
trigger O O
neoplastic O O
transformation O O
. O O

E6 O O
E7 O O
high-risk B-virus O
( O O
HR B-virus O
) O O
HPV E-virus B-virus
subtypes O O
bind O O
p53 O O
release O O
E2F O O
abrogate O O
replication O O
control O O
. O O

Due O O
variable O O
amino O O
acid O O
sequence O O
( O O
AAS O O
) O O
binding O O
sites O O
E6 O O
E7 O O
particular O O
HR-HPV B-virus B-virus
variants O O
within O O
subtypes O O
essentially O O
heterogeneous O O
efficacy O O
triggering O O
neoplastic O O
transformation O O
cancer O O
development O O
. O O

This O O
could O O
explain O O
differences O O
clinical O O
course O O
HPV-driven B-virus B-virus
head O O
neck O O
cancer O O
. O O

The O O
presence O O
HPV B-virus B-virus
DNA O O
necessarily O O
reflect O O
transcriptionally O O
active O O
virus B-virus B-virus
tumors O O
; O O
hence O O
, O O
important O O
consider O O
fact O O
categorizing O O
HPV-associated B-virus B-virus
tumors O O
. O O

Lymphoepithelial-like O O
carcinomas O O
( O O
LELC O B-virus
) O O
head O O
neck O O
represent O O
malignant O O
neoplasms O O
histologically O O
similar O O
nasopharyngeal O O
carcinoma O O
( O O
NPC O O
) O O
, O O
nonkeratinizing O O
undifferentiated O O
type O O
arise O O
locations O O
nasopharynx O O
. O O

The O O
common O O
location O O
LELC O B-virus
head O O
neck O O
salivary O O
glands O O
, O O
particular O O
parotid O O
gland O O
. O O

However O O
, O O
LELC O O
may O O
arise O O
sites O O
including O O
oropharynx O O
( O O
tonsils O O
, O O
base O O
tongue O O
) O O
, O O
sinonasal O O
tract O O
, O O
larynx O O
, O O
middle O O
ear/temporal O O
bone O O
. O O

Unlike O O
nonkeratinizing O O
undifferentiated O O
type O O
NPC O O
etiologically O O
linked O O
Epstein-Barr B-virus B-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
, O O
LELCs O O
uniformly O O
associated O O
EBV B-virus B-virus
. O O

The O O
differential O O
diagnosis O O
LELC O B-virus
varies O O
per O O
site O O
depending O O
site O O
occurrence O O
may O O
include O O
lymphoepithelial O O
sialadenitis O O
, O O
sinonasal O O
undifferentiated O O
carcinoma O O
( O O
SNUC O O
) O O
, O O
large O O
cell O O
neuroendocrine O O
carcinoma O O
. O O

Treatment O O
general O O
includes O O
combined O O
( O O
multimodality O O
) O O
therapy O O
including O O
surgical O O
resection O O
, O O
neck O O
dissection O O
, O O
radiation O O
therapy O O
and/or O O
chemotherapy O O
. O O

The O O
prognosis O O
may O O
vary O O
per O O
site O O
overall O O
favorable O O
owing O O
good O O
response O O
therapy O O
. O O

The O O
incidence O O
HPV B-virus B-virus
associated O O
head O O
neck O O
cancer O O
rising O O
. O O

Multiple O O
professionals O O
including O O
dental O O
hygienist O O
work O O
collaboratively O O
confront O O
growing O O
public O O
health O O
concern O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
, O O
usually O O
type O O
16 O O
, O O
emerged O O
aetiological O O
prognostic O O
marker O O
oropharyngeal O O
carcinomas O O
, O O
epidermal O O
growth O O
factor O O
receptor O O
( O O
EGFR O O
) O O
associated O O
poor O O
prognosis O O
patients O O
carcinoma O O
head O O
neck O O
. O O

This O O
makes O O
identification O O
cancers O O
associated O O
biomarkers O O
important O O
management O O
patients O O
. O O

We O O
surveyed O O
UK O O
head O O
neck O O
multidisciplinary O O
teams O O
email O O
using O O
online O O
form O O
assess O O
use O O
biomarker O O
testing O O
. O O

Overall O O
33 O O
cancer O O
networks O O
contacted O O
28 O O
( O O
85 O O
% O O
) O O
responded O O
. O O

HPV B-virus B-virus
tests O O
used O O
departments O O
22 O O
( O O
79 O O
% O O
) O O
respondents O O
, O O
3 O O
( O O
11 O O
% O O
) O O
used O O
EGFR O O
tests O O
. O O

The O O
commonest O O
reasons O O
using O O
lack O O
availability O O
lack O O
clinical O O
indication O O
. O O

The O O
purpose O O
study O O
develop O O
CMCSCC-1 O B-virus
cell O O
line O O
head O O
neck O O
cancer O O
research O O
new O O
therapies O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
. O O

Over O O
last O O
two O O
decades O O
, O O
recognized O O
head O O
neck O O
cancers O O
, O O
primarily O O
oropharynx O O
, O O
distinct O O
entity O O
causally O O
related O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
. O O

Fakhry O O
et O O
al O O
. O O

established O O
2008 O O
tumors O O
strikingly O O
better O O
prognosis O O
improved O O
responsiveness O O
chemotherapy O O
well O O
chemoradiotherapy O O
favorable O O
survival O O
rates O O
. O O

Since O O
, O O
new O O
studies O O
contributed O O
increased O O
understanding O O
new O O
entity O O
, O O
ranging O O
detailed O O
understanding O O
genetic O O
fingerprint O O
risk O O
modifiers O O
smoking O O
successful O O
early O O
attempts O O
personalize O O
therapy O O
de-escalation O O
definitive O O
intent O O
treatment O O
setting O O
specific O O
evaluation O O
targeted O O
therapies O O
patient O O
population O O
. O O

This O O
Commentary O O
seeks O O
summarize O O
state O O
art O O
understanding O O
HPV-associated B-virus B-virus
head O O
neck O O
cancers O O
emerged O O
since O O
publication O O
seminal O O
findings O O
Fakhry O O
et O O
al O O
. O O

HPV B-virus B-virus
DNA O O
detected O O
36/174 O O
( O O
~21 O O
% O O
) O O
samples O O
: O O
36 O O
% O O
cancers O O
oropharynx O O
; O O
31 O O
% O O
oral O O
cancers O O
, O O
22 O O
% O O
larynx O O
. O O

HPV-16 B-virus B-virus
common O O
, O O
present O O
33 O O
samples O O
, O O
followed O O
HPV-33 B-virus O
( O O
2 O O
samples O O
) O O
HPV-31 B-virus O
( O O
1 O O
sample O O
) O O
. O O

Twenty-eight O O
174 O O
samples O O
positive O O
p16 O O
, O O
predominantly O O
HPV-positive B-virus B-virus
tissues O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

No O O
statistically O O
significant O O
association O O
observed O O
cellular O O
markers O O
HPV B-virus B-virus
DNA O O
positive O O
cases O O
. O O

However O O
, O O
p16 O O
positivity O O
excellent O O
predictive O O
value O O
presence O O
HPV B-virus B-virus
PCR O O
. O O

Head O O
neck O O
squamous O O
cell O O
carcinomas O O
( O O
HNSCC O O
) O O
sixth O O
common O O
malignancy O O
globally O O
, O O
increasing O O
proportion O O
oropharyngeal O O
HNSCCs O O
associated O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
. O O

Patients O O
HPV-associated B-virus B-virus
tumours O O
markedly O O
improved O O
overall O O
disease-specific O O
survival O O
compared O O
HPV-negative B-virus B-virus
counterparts O O
treated O O
chemoradiation O O
. O O

Although O O
difference O O
outcomes O O
two O O
groups O O
clearly O O
established O O
, O O
mechanism O O
underlying O O
differences O O
remains O O
area O O
investigation O O
. O O

Data O O
preclinical O O
, O O
clinical O O
genomics O O
studies O O
started O O
suggest O O
increase O O
radio-sensitivity O O
HPV-positive B-virus B-virus
HNSCC O O
may O O
responsible O O
improved O O
outcomes O O
, O O
putative O O
mechanisms O O
review O O
. O O

The O O
Cancer O O
Genome O O
Atlas O O
others O O
recently O O
documented O O
multitude O O
molecular O O
differences O O
HPV-positive B-virus B-virus
HPV-negative B-virus B-virus
tumours O O
. O O

Preclinical O O
investigations O O
multiple O O
groups O O
explored O O
possible O O
mechanisms O O
increased O O
sensitivity O O
therapy O O
, O O
including O O
examining O O
differences O O
DNA O O
repair O O
, O O
hypoxia O O
immune O O
response O O
. O O

In O O
addition O O
differences O O
response O O
therapy O O
, O O
groups O O
started O O
investigate O O
phenotypic O O
differences O O
two O O
diseases O O
, O O
tumour O O
invasiveness O O
. O O

Finally O O
, O O
conclude O O
brief O O
review O O
ongoing O O
clinical O O
trials O O
attempting O O
de-escalate O O
treatment O O
minimise O O
long-term O O
toxicity O O
maintaining O O
cure O O
rates O O
. O O

New O O
insights O O
preclinical O O
genomic O O
studies O O
may O O
eventually O O
lead O O
personalised O O
treatment O O
paradigms O O
HPV-positive B-virus B-virus
patients O O
. O O

Our O O
data O O
compatible O O
idea O O
TTV B-virus B-virus
might O O
act O O
cocarcinogen O O
certain O O
cases O O
HNCC O O
. O O

Alternatively O O
, O O
HNCC O O
may O O
facilitate O O
either O O
TTV B-virus B-virus
replication O O
TTV B-virus B-virus
entry O O
saliva O O
. O O

A O O
case O O
note O O
review O O
performed O O
patients O O
undergoing O O
primary O O
surgery O O
oropharyngeal O O
cancer O O
single O O
centre O O
10-year O O
period O O
. O O

Human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
status O O
determined O O
via O O
dual O O
modality O O
testing O O
. O O

Associations O O
clinicopathological O O
variables O O
survival O O
identified O O
using O O
log-rank O O
test O O
. O O

The O O
characterization O O
analyses O O
revealed O O
typical O O
epithelial O O
morphology O O
; O O
doubling O O
time O O
approximately O O
24 O O
hours O O
, O O
high O O
tumorigenicity O O
immunodeficient O O
mice O O
, O O
upregulated O O
biomarkers O O
. O O

CMCSCC-1 O O
cells O O
negative O O
human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
, O O
sensitive O O
radiation O O
compared O O
FaDu O O
cell O O
lines O O
. O O

HC-2 O O
reliable O O
method O O
determining O O
HPV B-virus B-virus
status O O
HNSCCs O O
. O O

Its O O
application O O
HNSCCs O O
may O O
reduce O O
costs O O
helping O O
localize O O
primary O O
site O O
diagnostic O O
work-up O O
well O O
decrease O O
interval O O
time O O
determining O O
HPV B-virus B-virus
status O O
would O O
relevant O O
providing O O
prognostic O O
information O O
patient O O
well O O
determining O O
eligibility O O
clinical O O
trials O O
targeting O O
unique O O
patient O O
population O O
. O O

The O O
future O O
outlook O O
regarding O O
current O O
Zika B-virus B-virus
virus E-virus E-virus
outbreak O O
Americas O O
remains O O
uncertain O O
. O O

What O O
certain O O
need O O
promptly O O
efficiently O O
address O O
research O O
gaps O O
understanding O O
clinical O O
outcomes O O
infection O O
environmental O O
factors O O
influence O O
emergence O O
meanwhile O O
improving O O
diagnostic O O
, O O
therapeutic O O
, O O
preventive O O
measures O O
disease O O
. O O

The O O
p53 O O
pro-apoptotic O O
tumour O O
suppressor O O
mutated O O
functionally O O
altered O O
cancers O O
. O O

In O O
epithelial O O
tumours O O
induced O O
'high-risk B-virus O
' I-virus O
mucosal I-virus O
human I-virus B-virus
papilloma I-virus I-virus
viruses E-virus E-virus
, O O
including O O
human O B-virus
cervical O O
carcinoma O O
growing O O
number O O
head-and-neck O O
cancers O O
, O O
p53 O O
degraded O O
viral O O
oncoprotein O O
E6 O O
( O O
ref O O
. O O

2 O O
) O O
. O O

In O O
process O O
, O O
E6 O O
binds O O
short O O
leucine O O
( O O
L O O
) O O
#NAME? O O
LxxLL O O
consensus O O
sequence O O
within O O
cellular O O
ubiquitin O O
ligase O O
E6AP O O
. O O

Subsequently O O
, O O
E6/E6AP O O
heterodimer O O
recruits O O
degrades O O
p53 O O
( O O
ref O O
. O O

4 O O
) O O
. O O

Neither O O
E6 O O
E6AP O O
separately O O
able O O
recruit O O
p53 O O
( O O
refs O O
3 O O
, O O
5 O O
) O O
, O O
precise O O
mode O O
assembly O O
E6 O O
, O O
E6AP O O
p53 O O
unknown O O
. O O

Here O O
solve O O
crystal O O
structure O O
ternary O O
complex O O
comprising O O
full-length O O
human B-virus B-virus
papilloma I-virus I-virus
virus I-virus E-virus
type I-virus O
16 E-virus E-virus
( O O
HPV-16 B-virus B-virus
) O O
E6 O O
, O O
LxxLL O O
motif O O
E6AP O O
core O O
domain O O
p53 O O
. O O

The O O
LxxLL O O
motif O O
E6AP O O
renders O O
conformation O O
E6 O O
competent O O
interaction O O
p53 O O
structuring O O
p53-binding O O
cleft O O
E6 O O
. O O

Mutagenesis O O
critical O O
positions O O
E6-p53 O O
interface O O
disrupts O O
p53 O O
degradation O O
. O O

The O O
E6-binding O O
site O O
p53 O O
distal O O
previously O O
described O O
DNA- O B-virus
protein-binding O O
surfaces O O
core O O
domain O O
. O O

This O O
suggests O O
, O O
principle O O
, O O
E6 O O
may O O
avoid O O
competition O O
cellular O O
factors O O
targeting O O
free O O
bound O O
p53 O O
molecules O O
. O O

The O O
E6/E6AP/p53 O O
complex O O
represents O O
prototype O O
viral O O
hijacking O O
ubiquitin-mediated O O
protein O O
degradation O O
pathway O O
p53 O O
tumour O O
suppressor O O
pathway O O
. O O

The O O
present O O
structure O O
provides O O
framework O O
design O O
inhibitory O O
therapeutic O O
strategies O O
oncogenesis O O
mediated O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
. O O

Human B-virus B-virus
papillomaviruses E-virus E-virus
( O O
HPV B-virus B-virus
) O O
require O O
activation O O
DNA O O
damage O O
response O O
( O O
DDR O O
) O O
order O O
undergo O O
successful O O
life O O
cycle O O
. O O

This O O
activation O O
presents O O
challenge O O
virus B-virus B-virus
infected O O
cell O O
: O O
viral O O
host O O
replication O O
proceed O O
presence O O
DDR O O
ordinarily O O
arrests O O
replication O O
; O O
HPV16 B-virus B-virus
infected O O
cells O O
retain O O
ability O O
proliferate O O
presence O O
DDR O O
ordinarily O O
arrests O O
cell O O
cycle O O
? O O

This O O
raises O O
question O O
: O O
HPV B-virus B-virus
activate O O
DDR O O
? O O

The O O
answers O O
questions O O
partially O O
understood O O
; O O
full O O
understanding O O
could O O
identify O O
novel O O
therapeutic O O
strategies O O
target O O
HPV B-virus B-virus
cancers O O
. O O

Here O O
, O O
propose O O
rapid O O
replication O O
8 O O
kb O O
double O O
stranded O O
circular O O
genome O O
infection O O
creates O O
aberrant O O
DNA O O
structures O O
attract O O
activate O O
DDR O O
proteins O O
. O O

Therefore O O
, O O
HPV B-virus B-virus
replication O O
presence O O
active O O
DDR O O
necessity O O
successful O O
viral O O
life O O
cycle O O
order O O
resolve O O
DNA O O
structures O O
viral O O
genomes O O
; O O
without O O
active O O
DDR O O
, O O
successful O O
replication O O
viral O O
genome O O
would O O
proceed O O
. O O

We O O
discuss O O
essential O O
role O O

Regarding O O
issue O O
coincidence O O
HPV-induced B-virus O
oropharyngeal O O
and/or O O
anogenital O O
cancers O O
couples O O
, O O
13 O O
case-reports O O
case-series O O
reported O O
9 O O
larger O O
studies O O
based O O
population-registries O O
. O O

Four O O
registry O O
studies O O
showed O O
increased O O
risk O O
cervical O O
cancer O O
partner O O
four O O
. O O

Among O O
four O O
positive O O
studies O O
, O O
odds O O
ratios O O
development O O
HPV-related B-virus B-virus
cancer O O
among O O
spouses O O
2.6 O O
6.7 O O
. O O

One O O
study O O
showed O O
increased O O
risk O O
tongue O O
tonsil O O
cancer O O
among O O
husbands O O
women O O
cervical O O
dysplasia O O
cancer O O
. O O

Overall O O
absolute O O
risk O O
increase O O
studies O O
small O O
, O O
order O O
1月3日 O O
% O O
, O O
although O O
potentially O O
underestimated O O
. O O

Indeed O O
, O O
studies O O
assessed O O
partner O O
's O O
cancer O O
risk O O
one O O
anatomical O O
site O O
whereas O O
HPV- B-virus O
related O O
malignancies O O
affect O O
different O O
locations O O
. O O

Head O O
neck O O
squamous O O
cell O O
carcinoma O O
( O O
HNSCC O O
) O O
sixth O O
common O O
cancer O O
world O O
600,000 O O
new O O
cases O O
diagnosed O O
annually O O
. O O

Tobacco O O
alcohol O O
use O O
associated O O
principal O O
etiological O O
factors O O
pathogenesis O O
. O O

The O O
incidence O O
smoking-associated O B-virus
HNSCC O O
declined O O
, O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
#NAME? O O
HNSCC O O
rise O O
. O O

There O O
currently O O
clinically O O
validated O O
biomarkers O O
detect O O
cancer O O
early O O
stage O O
( O O
cancers O O
independent O O
HPV B-virus B-virus
status O O
) O O
. O O

It O O
well-established O O
aberrant O O
expression O O
miRNAs O O
lead O O
tumorigenesis O O
. O O

miRNA O O
expression O O
differences O O
also O O
demonstrated O O
HPV-positive B-virus B-virus
HPV-negative B-virus B-virus
HNSCC O O
tumor O O
tissues O O
well O O
body O O
fluids O O
. O O

Therefore O O
, O O
miRNAs O O
potential O O
provide O O
unprecedented O O
insight O O
pathogenesis O O
HNSCC O O
serve O O
potential O O
biomarkers O O
. O O

This O O
review O O
addresses O O
HNSCC O O
disease O O
burden O O
regulation O O
miRNA O O
HPV B-virus B-virus
viral O O
oncoproteins O O
, O O
potential O O
miRNA O O
biomarkers O O
future O O
perspectives O O
. O O

miRNA O O
provides O O
unique O O
opportunity O O
fulfill O O
current O O
clinical O O
challenge O O
HNSCC O O
patient O O
management O O
enabling O O
early O O
detection O O
followed O O
targeted O O
interventions O O
, O O
leading O O
significant O O
reduction O O
mortality O O
morbidity O O
. O O

Brown O O
adipose O O
tissue O O
constituent O O
brown O O
adipocytes O O
promising O O
therapeutic O O
target O O
metabolic O O
disorders O O
due O O
ability O O
dissipate O O
energy O O
improve O O
systemic O O
insulin O O
sensitivity O O
glucose O O
homeostasis O O
. O O

The O O
molecular O O
control O O
brown O O
adipocyte O O
differentiation O O
function O O
extensively O O
studied O O
mice O O
, O O
relatively O O
little O O
known O O
regulatory O O
mechanisms O O
humans O O
, O O
part O O
due O O
lack O O
human O O
brown O O
adipose O O
tissue O O
derived O O
cell O O
models O O
. O O

Here O O
, O O
used O O
retrovirus-mediated O O
overexpression O O
stably O O
integrate O O
human O O
telomerase O O
reverse O O
transcriptase O O
( O O
TERT O O
) O O
stromal-vascular O O
cell O O
fractions O O
deep O O
superficial O O
human O O
neck O O
adipose O O
tissue O O
biopsies O O
donor O O
. O O

The O O
brown O O
white O O
pre-adipocyte O O
cell O O
models O O
( O O
TERT-hBA O O
TERT-hWA O O
, O O
respectively O O
) O O
displayed O O
stable O O
proliferation O O
rate O O
differentiation O O
least O O
passage O O
20 O O
. O O

Mature O O
TERT-hBA O O
adipocytes O O
expressed O O
higher O O
levels O O
thermogenic O O
marker O O
genes O O
displayed O O
higher O O
maximal O O
respiratory O O
capacity O O
mature O O
TERT-hWA O O
adipocytes O O
. O O

TERT-hBA O O
adipocytes O O
UCP1-positive O O
responded O O
尾-adrenergic O O
stimulation O O
activating O O
PKA-MKK3/6-p38 O O
MAPK O O
signaling O O
module O O
increasing O O
thermogenic O O
gene O O
expression O O
oxygen O O
consumption O O
. O O

Mature O O
TERT-hWA O O
adipocytes O O
underwent O O
efficient O O
rosiglitazone-induced O O
'browning O B-virus
' O O
, O O
demonstrated O O
strongly O O
increased O O
expression O O
UCP1 O O
brown O O
adipocyte-enriched O O
genes O O
. O O

In O O
summary O O
, O O
TERT-hBA O O
TERT-hWA O B-virus
cell O O
models O O
represent O O
useful O O
tools O O
obtain O O
better O O
understanding O O
molecular O O
control O O
human O O
brown O O
white O O
adipocyte O O
differentiation O O
function O O
well O O
browning O O
human O O
white O O
adipocytes O O
. O O

Head O O
neck O O
cancers O O
sixth O O
common O O
cancer O O
world O O
predominant O O
type O O
consist O O
squamous O O
cell O O
carcinomas O O
( O O
head O O
neck O O
squamous O O
cell O O
carcinoma O O
, O O
HNSCC O O
) O O
. O O

Besides O O
tobacco O O
smoking O O
alcohol O O
consumption O O
, O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
infection O O
third O O
leading O O
cause O O
occurrence O O
HNSCC O O
. O O

The O O
presence O O
HPV B-virus B-virus
distinct O O
group O O
head O O
neck O O
cancers O O
exhibiting O O
epidemiological O O
, O O
histopathological O O
, O O
clinical O O
prognostic O O
differences O O
opposed O O
typical O O
HNSCC O O
. O O

HPV B-virus B-virus
positive O O
HNSCC O O
normally O O
favorable O O
prognosis O O
compared O O
HPV B-virus B-virus
negative O O
HNSCC O O
, O O
biomarkers O O
suitable O O
early O O
detection O O
HPV B-virus B-virus
positive O O
HNSCC O O
developed O O
urgently O O
improve O O
patient O O
outcomes O O
. O O

HPV B-virus B-virus
DNA O O
screening O O
sensitive O O
, O O
probably O O
useful O O
high O O
prevalence O O
oral O O
HPV B-virus B-virus
low O O
risk O O
HNSCC O O
. O O

MicroRNAs O O
( O O
miRNAs O O
) O O
constitute O O
class O O
small O O
non-coding O O
RNAs O O
act O O
post-transcriptional O O
regulators O O
gene O O
expression O O
. O O

Since O O
miRNAs O O
role O O
cancer O O
development O O
HPV B-virus B-virus
status O O
may O O
affect O O
miRNAs O O
expression O O
pattern O O
HNSCC O O
, O O
specific O O
miRNAs O O
' O O
expression O O
HPV B-virus B-virus
positive O O
HNSCC O O
may O O
expound O O
role O O
HPV B-virus B-virus
HNSCC O O
new O O
biomarkers O O
early O O
detection O O
HNSCC O O
. O O

More O O
excitingly O O
, O O
saliva O O
proximal O O
biofluid O O
context O O
HNSCC O O
contains O O
good O O
deal O O
miRNAs O O
. O O

These O O
miRNAs O O
stabile O O
may O O
suitable O O
noninvasive O O
biomarkers O O
HNSCC O O
. O O

Viral O O
gene O O
therapy O O
promising O O
new O O
treatment O O
modality O O
head O O
neck O O
cancer O O
. O O

This O O
paper O O
provides O O
reader O O
review O O
relevant O O
literature O O
field O O
. O O

Increases O O
incidence O O
oropharyngeal O O
squamous O O
cell O O
carcinoma O O
( O O
OPSCC O O
) O O
countries O O
falling O O
tobacco O O
use O O
attributed O O
growing O O
role O O
human B-virus B-virus
papilloma I-virus I-virus
virus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
carcinogenesis O O
. O O

Trends O O
HPV B-virus B-virus
prevalence O O
populations O O
persistently O O
high O O
portions O O
smokers O O
poorly O O
characterised O O
. O O

In O O
recent O O
years O O
well O O
established O O
two O O
major O O
constituent O O
parts O O
ubiquitin O O
proteasome O O
system O O
( O O
UPS O O
) O O
#NAME? O O
proteasome O O
holoenzymes O O
number O O
ubiquitin O O
ligases-play O O
crucial O O
role O O
, O O
virus B-virus B-virus
replication O O
also O O
regulation O O
immunogenicity O O
human B-virus B-virus
immunodeficiency I-virus I-virus
virus E-virus E-virus
type O O
1 O O
( O O
HIV-1 B-virus B-virus
) O O
. O O

However O O
, O O
role O O
HIV-1 B-virus B-virus
replication O O
third O O
major O O
component O O
, O O
deubiquitinating O O
enzymes O O
( O O
DUBs O O
) O O
, O O
remained O O
largely O O
unknown O O
. O O

In O O
study O O
, O O
show O O
DUB-inhibitors O O
( O O
DIs O O
) O O
P22077 O O
PR-619 O O
, O O
specific O O
DUBs O O
USP7 O O
USP47 O O
, O O
impair O O
Gag O O
processing O O
thereby O O
reduce O O
infectivity O O
released O O
virions O O
without O O
affecting O O
viral O O
protease O O
activity O O
. O O

Furthermore O O
, O O
replication O O
capacity O O
X4- O O
R5-tropic O O
HIV-1 B-virus B-virus

Although O O
acute O O
Zika B-virus B-virus
virus E-virus E-virus
infection O O
typically O O
mild O O
self-limited O O
, O O
researchers O O
demonstrated O O
serious O O
neurologic O O
complications O O
associated O O
microcephaly O O
Guillain-Barre O O
syndrome O O
. O O

Otolaryngologists O O
aware O O
head O O
neck O O
manifestations O O
include O O
conjunctivitis O O
, O O
retro-orbital O O
pain O O
, O O
cephalgia O O
, O O
odynophagia O O
. O O

The O O
Centers O O
Disease O O
Control O O
Prevention O O
developed O O
specific O O
molecular O O
serologic O O
testing O O
protocols O O
algorithms O O
follow-up O O
care O O
suspected O O
cases O O
. O O

Currently O O
, O O
mainstay O O
management O O
conservative O O
care O O
researchers O O
attempt O O
develop O O
vaccine O O
. O O

Strategies O O
contain O O
Zika B-virus B-virus
virus E-virus E-virus
include O O
vector O O
control O O
, O O
travel O O
restriction O O
women O O
pregnant O O
trying O O
become O O
pregnant O O
, O O
avoidance O O
mosquito O O
bites O O
endemic O O
regions O O
world O O
. O O

Head O O
neck O O
cancers O O
( O O
HNC O O
) O O
one O O
common O O
cancers O O
India O O
. O O

Human B-virus B-virus
papillomavirus E-virus E-virus
( O O
HPV B-virus B-virus
) O O
identified O O
emerging O O
risk O O
factor O O
HNC O O
. O O

Epstein B-virus B-virus
Barr I-virus I-virus
virus E-virus E-virus
( O O
EBV B-virus B-virus
) O O
#NAME? O O
lymphoproliferative O O
processes O O
occur O O
head O O
neck O O
ranging O O
reactive O O
processes O O
infectious O O
mononucleosis O O
high O O
grade O O
malignant O O
lymphomas O O
. O O

EBV B-virus B-virus
ubiquitous O O
herpes O B-virus
virus B-virus E-virus
infects O O
90 O O
% O O
adults O O
worldwide O O
, O O
generally O O
transferred O O
though O O
saliva O O
. O O

Primary O O
infection O O
occur O O
throughout O O
life O O
. O O

EBV B-virus B-virus
first O O
virus B-virus E-virus
linked O O
malignancies O O
, O O
epithelial O O
lymphoid O O
. O O

Both O O
T O O
B O O
cell O O
lymphomas O O
associated O O
EBV B-virus B-virus
evidence O O
shows O O
individual O O
's O O
response O O
acute O O
EBV B-virus B-virus
infection O O
may O O
critical O O
development O O
subsequent O O
lymphoma O O
. O O

Currently O O
, O O
situ O O
hybridization O O
EBER O O
sensitive O O
available O O
test O O
detect O O
EBV B-virus B-virus
routinely O O
performed O O
lymphoproliferative O O
lesions O O
head O O
neck O O
. O O

Immunohistochemistry O O
EBV B-virus B-virus
related O O
proteins O O
, O O
LMP1 O B-virus
, O O
much O O
less O O
sensitive O O
EBER O O
situ O O
hybridization O O
, O O
help O O
determine O O
latency O O
patterns O O
EBV B-virus B-virus
infection O O
. O O

Although O O
relatively O O
rare O O
, O O
primary O O
EBV-related B-virus B-virus
lymphomas O O
must O O
considered O O
differential O O
atypical O O
lymphoid O O
proliferations O O
head O O
neck O O
. O O

We O O
present O O
selected O O
EBV-related B-virus O
disorders O O
head O O
neck O O
discussing O O
etiology O O
well O O
differential O O
diagnosis O O
. O O

